Evaluation of Anti-Malarial Effects of Mass Chemoprophylaxis in the Republic of Korea Army by Yeom, Joon-Sup et al.
INTRODUCTION
Plasmodium vivax, the causative agent of vivax malaria, is
the second most common species of malaria with a yearly
estimate of 35 million cases worldwide (1). Prior to the 1970’s
when the Republic of Korea (ROK) was determined to be
‘‘malaria free’’, vivax malaria was a significant civilian and
military public health threat (2-4). During the Korean War
(1950-1953), the ROK and U.S. military suffered many casu-
alties as a result of vivax malaria. For example, approximately
15% of all febrile illnesses among ROK military personnel
were due to malaria (2-5). With the initial use of chloroquine,
U.S. casualties in the ROK were decreased, but cases soon
showed up in the U.S. as a result of hypnozoites. The discov-
ery of primaquine and its use soon reduced malaria casualties
among U.S. soldiers throughout the remainder of the war (6).
Even so, during 1953 at the end of the war, more than 3,000
U.S. soldiers and nearly 9,000 ROK Army soldiers were diag-
nosed with malaria (7). Following the signing of the armistice
and reduced hostilities in 1954, malaria cases decreased to
fewer than 6,000 among ROK Army soldiers (8). As socio-
economic conditions in the ROK improved and associated
malaria control efforts were strengthened, the ROK was de-
clared ‘‘malaria free’’ in 1979 (4). However, focal indigenous
cases continued to be reported through 1984 (9).
It was not until 1993 that vivax malaria returned with a
vengeance along the demilitarized zone (DMZ), increasing
exponentially through 2000 (4,142 cases), and only decreas-
ing through 2002 as a result of an extensive chemoprophy-
laxis program instituted by the ROK Army among combat
units assigned to ‘‘high-risk’’ areas near the DMZ (10-14).
Almost all of the re-emerging malaria cases have been con-
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Evaluation of Anti-Malarial Effects of Mass Chemoprophylaxis in the
Republic of Korea Army
Vivax malaria was endemic on the Korean peninsula for many centuries until the
late 1970
,
s when the Republic of Korea (ROK) was declared   malaria free
,,
. Since
its re-emergence in 1993, the number of malaria cases in the military increased
exponentially through 2000 near the demilitarized zone. Chemoprophylaxis with
chloroquine and primaquine has been used in the ROK Army since 1997 in an attempt
to reduce the number of the malaria cases throughout the ROK. Data show that
chemoprophylaxis contributed, in part, to the decrease in the number of malaria
cases among military personnel. However, mass chemoprophylaxis on a large scale
in the ROK Army is unprecedented and extensive supervision and monitoring is
warranted to determine its effectiveness and to monitor the appearance of chloro-
quine tolerant/resistant strains of Plasmodium vivax.
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fined to the northern part of Gyeonggi Province and the north-
western part of Gangwon Province near the DMZ, where
large numbers of soldiers are stationed. Because of this geo-
graphical distribution and exposure of personnel during train-
ing/operations, most cases were reported among soldiers since
the beginning of the epidemic. To cope with the exponen-
tially increasing malaria rates among various military units,
chemoprophylaxis (chloroquine followed with terminal pri-
maquine) was initiated among military personnel assigned
to ‘‘malaria high-risk areas’’ in 1997 in an attempt to reduce
malaria rates among soldiers and spread to civilian popula-
tions throughout the ROK. The chemoprophylaxis program
was expanded annually from approximately 16,000 (1997)
to more than 140,000 in 2002. Decreased numbers of malaria
cases experienced by the ROK Army were attributed to the
annual expansion of chemoprophylaxis in ‘‘high-risk’’ malaria
areas, especially since 1999 (12). While mass chemoprophy-
laxis was used on a large scale among U.S. soldiers during the
Korean War, the use of large-scale chemoprophylaxis in the
ROK Army is unprecedented. Therefore, an evaluation of
the effectiveness of the chemoprophylaxis program is required
not only to determine its effect on the reduction of malaria
cases, but also to monitor for increased parasite tolerance/resist-
ance to chloroquine and/or primaquine. In this study, we
evaluated the effects of disease reduction of mass chemopro-
phylaxis for selected ROK Army units, i.e., monthly and
annual incidence, geographic dispersion and direct compar-
ison on the number of malaria cases of neighboring units.
MATERIALS AND METHODS
Malaria, defined as, any febrile illness and demonstration
of P. vivax parasites in peripheral blood smears, is a reportable
disease to the Ministry of Health and Welfare, ROK (4, 15).
All malaria cases among ROK military personnel are reported
to the Office of the Surgeon General, Army Headquarters, to
the Ministry of Health and Welfare. All cases of vivax malaria
that were reported to the Korean Ministry of National De-
fense from 1 January 1993 through 31 December 2002 were
reviewed and their epidemiological characteristics, e.g., date
of disease onset, status of receiving chemoprophylaxis and
location of their service unit, analyzed.
Malaria case data among ROK military veterans (most after
serving 26 months) and civilians were acquired from the
Department of Epidemiology, National Institute of Health
(Seoul, Republic of Korea). Cases among military veterans
were defined as those who 1) developed malaria within 24
months after discharge from military service, and 2) had been
stationed during their military services in a malaria-risk area.
Otherwise, veterans were reported as civilians. All of the cases
defined here as ‘‘military veterans’’ were excluded from this
study since most did not complete terminal primaquine pro-
phylaxis in the year that they were discharged from military
service. ‘‘Malaria-risk’’ areas were reported during the preced-
ing year(s) as those areas where malaria cases were reported.
Epidemiologic characteristic data from civilians were com-
pared with the data from ROK military personnel. 
To evaluate the effects of mass chemoprophylaxis, we iden-
tified paired military units (chemoprophylaxis and no chemo-
prophylaxis) located within a 1.5-kilometer radius, and similar
levels of malaria prevalence and socio-behavioral conditions.
Also, we analyzed the occurrence of malaria cases between
neighboring units during the same periods. Data for each unit,
including the unit branch, location, the number of soldiers,
and training situation, were obtained through interviews with
corresponding unit medical officers. Soldiers received weekly
oral 400 mg-hydroxychloroquine sulfate (HaloxinTM, Han Lim
Pharmaceutical Co., Republic of Korea, AruquinTM, Unimed
Pharmaceutical Inc., Republic of Korea, RumaqinTM, Hana
Pharmaceutical Co., Republic of Korea) from June through
early October followed by daily oral 15 mg-primaquine
phosphate (PraquineTM, Daewoo Pharmaceutical Co., Repub-
lic of Korea, MalaquinTM, Ahn Gook Pharmaceutical Co.,
Republic of Korea) for two weeks. Test for glucose-6-phos-
phate deficiency before primaquine prophylaxis was not done
because it is very rare in Koreans.
The statistical analysis for the data was done with SAS ver-
sion 8.0 (SAS Institute Inc., Cary, North Carolina, U.S.A.).
Comparisons of malaria incidence between treatment and
control groups were made by Mantel-Haenszel  2-test. The
primary efficacy parameter was based on malaria rates of the
paired treatment and control groups, such that: efficacy of
chemoprophylaxis=1-[(rate of disease among the chloroquine/
primaquine treatment group)/(rate of disease among the con-
trol group)].
RESULTS
The ROK Army initiated chemoprophylaxis to nearly
16,000 soldiers in 1997 (Table 1). The numbers of soldiers
administered chemoprophylaxis increased thereafter until
more than 140,000 soldiers were provided chemoprophylaxis
Year
Number of
soldiers
Day of first
medication*
Day of last
medication*
1997 15,981 June 19 September 30
1998 37,529 June 8 October 15
1999 61,772 June 7 October 11
2000 Over 90,000 June 5 October 9
2001 Over 110,000 May 14 September 24
2002 Over 140,000 May 13 September 23
Table 1. Number of Republic of Korea Army soldiers provided
chloroquine/primaquine chemoprophylaxis from 1997 through
2002
*Day of first medication and day of last medication represent day of first
and last taking of chloroquine, respectively.Chemoprophylaxis of Malaria in Korean Army  709
by 2002. The prophylactic schedule was initiated about mid-
June in 1997. In subsequent years, malaria chemoprophylaxis
was initiated during the 1st and 2nd weeks of June until 2000.
During 2001 and 2002, it was initiated during the 2nd week
of May.
Prior to the initiation of chemoprophylaxis, the ROK Army
accounted for >80% of all malaria cases (Table 2). With the
introduction of chemoprophylaxis in 1997 and subsequent
years, the proportion of military cases accounted for 67%
(1997) to 24% (2002). During 1999 through 2002, a decrease
in malaria incidence in the military occurred approximately
1-2 weeks after the chemoprophylaxis schedule was initiated
in early June or in mid-May (Fig. 1). This was inconsistent
with the steady increase of malaria cases among civilian popula-
tions that were not provided chemoprophylaxis. The propor-
tion of annual cases among military members for the period
when chemoprophylaxis was initiated to one week after the
final dose of chloroquine during 1999 through 2002 was 71%
(771/1,085), 75% (960/1,288), 82% (550/673) and 80%
(338/425) of the total annual number of cases, respectively.
On the other hand, the proportion of annual malaria cases
among civilian populations was 87% (1,337/1,541) in 1999,
88% (1,333/1,515) in 2000, 87% (963/1,112) in 2001 and
88% (760/864) in 2002 during this same period.
Year 1993 1994 1995 1996 1997 1998 1999 2000 2001 2002
Annual military cases (a) 1 18 88 287 1,155 1,655 1,085 1,288 673 425
Annual cases in areas of highest prevalence (b) 1 14 85 267 1,048 1,474 785 876 398 239
Annual total cases (c) 1 21 107 356 1,724 3,932 3,621 4,142 2,540 1,757
% (b/c) 100 77.7 96.5 93.0 90.7 89.0 72.3 68.0 59.1 56.2
% (a/c) 100 85.7 82.2 80.2 67.0 42.1 29.9 31.1 26.5 24.2
Table 2. Proportion of total Republic of Korea military cases and annual military malaria cases in areas of highest prevalence (Paju,
Yeoncheon, and Cheolwon Counties) compared to the total number of annual malaria cases reported by the Korean National Insti-
tute of Health
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Fig. 1. Ten-day incident cases of malaria involving soldiers and civilians in the Republic of Korea from January 1999 through December
2002. Arrows represent the starting point of chemoprophylaxis in each year.
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Through 1997, more than 90% of the total military cases
occurred in areas of highest prevalence including Yeoncheon,
Paju, and Cheolwon Counties where chemoprophylaxis was
provided at the early stage. Case occurrences in these regions
gradually decreased to 56% by 2002 (Table 2).
Risk factors for the potential exposure to infected anophe-
line mosquitoes, including geographic and socio-behavioral
for ROK Army units are shown in Table 3. The occurrence
of malaria among paired units is shown in Table 4. Units A
and B were infantry units located in Paju County approxi-
mately 3 km from the DMZ and with missions to patrol activ-
ity along the DMZ. Due to its higher malarial rates in 1997,
Unit A was provided chemoprophylaxis from 1998 through
2000. Chemoprophylaxis was initiated for Unit B in 1999
when malaria rates reached 4%.
Units C and D were similarly located in Paju County. Unit
C and D were approximately 4 km and 4.5 km from the
DMZ, respectively. Unit C (infantry unit) had more frequent
field and night training missions than Unit D (artillery unit).
Chemoprophylaxis was initiated in Unit C in 1999 and in
Unit D in 2000. The incidence of malaria was similar between
these groups in 1997 and 1998 (p>0.05) but the incidence
was significantly lower in the unit C in 1999 (p<0.001). In
1999, when chemoprophylaxis was initiated, malaria inci-
dence of Unit C was less than one-seventh of that of Unit D
in spite of greater potential of exposure to the vector popu-
lations (Table 4). 
Units E and F were located within 2 km of each other in
Cheolwon County, approximately 4 km from the DMZ. Che-
moprophylaxis was initiated in Unit E in 1998 but was not
performed in Unit F. Units E and F showed no significant
difference in the incidence of malaria in 1997 (p>0.05). All
ROK Army units given chemoprophylaxis demonstrated
significantly lower incidence rates of malaria when compared
to untreated units (p>0.05). The efficacy of chemoprophylaxis,
based on malaria rates among treated and untreated units,
ranged 80-100%.
DISCUSSION
Vivax malaria in Korea is characterized as unstable malar-
ia, e.g., low rates of disease with occasional local epidemics
due to environmental factors, topography, agricultural change
(reduction of livestock in North Korea), inefficient vector con-
trol, and political and socioeconomic factors (17). Additional
factors contributing to the instability of malaria transmission
in the ROK include a short transmission season (May through
October) and high vector populations (17).
Since its re-emergence in 1993, malaria cases had grown
exponentially through 1997 (11, 12). During this period,
Year 1997 1998 1999 2000
Unit A 33 (5.5) 0 (0) 6 (1) 0 (0)
Unit B 6 (0.85) 28 (4) 4 (0.57) 1 (0.14)
Relative risk 6.42
� 0.00
� 1.75 0.00
(95% CI*) (2. 71-15.21) (0.00-0.20) (0.50-6.17) (0.00-20.21)
Efficacy of  N/A 100% (NA
�) N/A N/A
prophylaxis
�(95% CI)
Unit C 9 (1.8) 5 (1) 3 (0.6) 5 (1)
Unit D 1 (0.28) 6 (1.71) 16 (4.57) 4 (1.14)
Relative risk 6.30 0.58 0.13
� 0.88
(95% CI) (0.80-49.50) (0.18-1.90) (0.04-0.45) (0.24-3.24)
Efficacy of  N/A N/A 80% (75-83) N/A
prophylaxis
�(95% CI)
Unit E 8 (1.33) 1 (0.16) 4 (0.66) 8 (1.33)
Unit F 4 (1.14) 8 (2.28) 13 (3.71) 26 (7.42)
Relative risk 1.17 0.07
� 0.18
� 0.18
�
(95% CI) (0.35-3.85) (0.07-0.58) (0.06-0.55) (0.08-0.39)
Efficacy of  92% 80% 80%
prophylaxis
�(95% CI) (91-94) (78-85) (77-86)
Table 4. Number and percent (  ) of malaria cases of paired units
located near the DMZ from 1997 through 2000. Underline iden-
tifies units that were provided chemoprophylaxis during that year
The comparison of malaria incidence between groups was tested by
Mantel-Haenszel 
2-test. *`95% CI'=95% confidence interval. 
� p-value
<0.01. 
� Efficacy of prophylaxis=1-[(rate of disease among the chloro-
quine/primaquine treatment group)/(rate of disease among the control
group)]. 
�NA, not applicable.
*Based on case locality data, units located nearer to the DMZ have increased malaria risk factors. 
� ,� Units with greater field and night training frequen-
cies have greater potential of exposure to the malaria vectors. Anopheles sinensis, the primary malaria vector in Korea, is exophilic, with peak feeding
activity during 11:00 PM and 3:00 AM the next day (3.16). 
�
Even with fewer days in the field and night, malaria rates in Units D and F continued to greatly
increase when not provided chemoprophylaxis.
Unit Unit branch County
Number of
soldiers
Distance from
the DMZ (Km)*
Mean annual field 
training frequency 
(days)
�
Mean annual night 
training frequency
(nights)
�
Assignment 
period at unit
(months)
A Infantry Paju 600 3 140 60 25
B Infantry Paju 700 3 140 60 25
C Infantry Paju 500 4 140 60 25
D Artillery Paju 350 4.5 100
� 40
� 25
E Infantry Cheolwon 600 4 140 60 25
F Artillery Cheolwon 350 4 100
� 40
� 25
Table 3. Characteristics of Republic of Korea Army units A through Fmore than 80% of the total number of annual cases occurred
in the ROK military, including veterans, and almost all of
them were assigned to units located near the DMZ (11, 12).
This resulted in a major health threat that the Korean Min-
istry of National Defense had to address, in addition to the
spread of malaria from military to civilian populations south
of the DMZ as veterans and travelers exposed to malaria in
endemic regions returned home. In 1997, the Korean Ministry
of National Defense addressed the increasing numbers and
spread of malaria throughout the ROK, in part, by initiating
a chemoprophylaxis policy using chloroquine and primaquine.
Soldiers received weekly oral 400 mg-hydroxychloroquine
sulfate from June through early October followed by daily
oral 15 mg-primaquine phosphate for two weeks (18-22). 
Compliance in any mass chemoprophylaxis program that
covers large populations is a major issue. While it was recom-
mended that military commanders and their staffs ensure
that all soldiers take chloroquine under direct observation,
some units failed to comply with this recommendation (8).
Thus, soldiers that contracted malaria in areas where chemo-
prophylaxis was provided may not have taken chloroquine
as directed. However, other factors that were not evaluated,
e.g., incomplete absorption of the drug or drugs that have
lost their potency due to inappropriate storage or expiration
may have resulted in some cases. Additionally, parasites may
develop a tolerance/resistance to blood concentrations of chloro-
quine in persons on chemoprophylaxis, creating an additional
burden on the public health system to use other more expen-
sive anti-malarial drugs or increase treatment regimens. These
factors must be considered and monitored whenever mass
chemoprophylaxis is planned or initiated to ensure a safe and
effective program. Since blood concentrations of chloroquine
were not determined for soldiers on chemoprophylaxis, there
is no evidence that the strains of vivax malaria circulating in
the ROK are tolerant/resistant to chloroquine therapy.
Even though there were malaria cases among the ‘‘treat-
ment groups’’ (chemoprophylaxis), they demonstrated a sig-
nificant reduction from the previous years while their paired
‘‘control groups’’ (no chemoprophylaxis) increased significantly
(12). We can find this phenomenon in Table 4. Even though
Units D and F had less exposure than their paired units, malar-
ia greatly increased in these units when not provided chemo-
prophylaxis while decreasing in their paired units when they
were given chemoprophylaxis. These results also demonstrate
that even with partial chemoprophylaxis in malaria ‘‘high-
risk’’ areas, malaria rates decreased while expanding in adja-
cent counties where chemoprophylaxis was not provided. The
positive effect in the reduction of malaria cases is further sup-
ported by evidence that when chemoprophylaxis was initiat-
ed, at about a one-week interval, malaria cases were reduced
in military populations, while they continued to increase
among civilian populations. Had the intervention of chemo-
prophylaxis not been instituted, it is assumed, based on civil-
ian data, that the malaria rates in the military populations
would have been much greater. If chemoprophylaxis was not
performed in the military, malaria cases might have increased
mainly during the prophylactic period, and it resulted in
similar proportion of malaria among military personnel for
prophylactic period with that among civilian populations for
same period. This also would have an impact on the number
of civilian/veteran cases by reducing secondary transmission
of the ‘‘prevented’’ cases. Overall reduction in malaria cases
in ROK Army might have been even greater if soldiers had
taken chloroquine completely as directed. But due to poor
compliance in some soldiers, malaria cases reported 
Previous U.S. experiences during the Korean War demon-
strated that large numbers of casualties as a result of malaria
were successfully reduced when mass chemoprophylaxis, using
chloroquine and later with terminal primaquine was applied
(5). Thus, historically the use of chemoprophylaxis in Korea
effectively reduced the malaria threat under wartime condi-
tions. Chloroquine usage continues to be the recommended
prophylactic regimen against vivax malaria where there is no
chloroquine-resistant parasites (18-22). Chemoprophylaxis
with chloroquine and primaquine on a large scale in the ROK
Army to reduce vivax malaria casualties provides an oppor-
tunity to evaluate the effect of mass chloroquine/primaquine
prophylaxis during armistice conditions (23). 
Results described herein show that chemoprophylaxis used
in high-risk malaria areas is at least one of the factors that
reduced malaria rates among units provided chemoprophy-
laxis. Several other factors might have contributed to overall
reduction in malaria cases in ROK Army such as wearing
permethrin-treated military uniform during malaria trans-
mission season and effort made by ROK Government to
improve malaria situation in North Korea. However, these
measures were not strictly carried out and although the effect
of these measures cannot be ignored, we can say that our results
represent mostly the effect of chemoprophylaxis. Currently
not being done, extensive supervision and surveillance is war-
ranted to ensure that endemic strains of P. vivax in Korea do
not become tolerant/resistant to current regimens of chloro-
quine and primaquine therapy.
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